FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

Check this box if no longer subject
to Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Secora Michael					2. Issuer Name and Ticker or Trading Symbol RECURSION PHARMACEUTICALS, INC. [RXRX]										heck all ap Dire	olicable)	ting Person(s) to I 10% O e Other (wner
(Last)	(Fir	rst) (f	/liddle)												belo	,		below)	· ·
C/O RECURSION PHARMACEUTICALS 41 S. RIO GRANDE STREET					3. Date of Earliest Transaction (Month/Day/Year) 08/15/2022										Chief Fina	ncial	Officer		
(Street)					4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)					
SALT LAKE LIT 84101														X Form	on				
CITY														Form filed by More than One Reporting Person					
(City)	(St	ate) (Z	<u>Z</u> ip)																
		Table	I - No	n-Deriva	tive S	Secu	rities	Acq	uired,	, Dis	posed of	, or	Ben	eficia	ally Owr	ed			
1. Title of Security (Instr. 3) 2. Transact Date (Month/Day				Executive (Year)		Deemed cution Date, y nth/Day/Year)		Transaction Disposed (Code (Instr. 5)		es Acquired (A Of (D) (Instr. 3,		(A) or 3, 4 an	d Secur Benef Owne	icially d Following	Form (D) o	n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership		
									Code	v	Amount	nount (A) or (D)		Price	Trans	Reported Transaction(s) (Instr. 3 and 4)			(Instr. 4)
Class A Common Stock 08/15/2					2022				F ⁽¹⁾		1,065	I	o	\$12.9	96 587,637			D	
		Tal									osed of, convertib					d			
Derivative Conversion Date		3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr. 8)				6. Date Expirat (Month		7. Title and Amount of Securities Underlying Derivative Security (Ins 3 and 4)		f 9	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercis	able	Expiration Date	Title	or Nur of	ount nber ires					

Explanation of Responses:

Remarks:

/s/ Jonathan Golightly, attorney-in-fact

08/17/2022

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

^{1.} Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units.